About Gene Therapy for Hemophilia: Dream or Reality?
Gene therapy has remained a constant prospect in the sphere of hemophilia treatment. For over two decades and the question remained: Is this just a dream, or could it one day become a reality?
Hemophilia gene therapy has finally been approved.
David Page talks to hemophilia specialists that will dive deep into understanding how the treatment works, its significance in advancing treatment, and how a one time treatment could change a severe condition to a milder one.Though not a definitive cure, gene therapy for hemophilia has transformed the dream of a cure into a reality for the future.
David and his guests will provide exclusive insights into one of the most significant medical breakthroughs of our era.
All About Von Willebrand Disease: Von Willebrand Disease 101
2026 marks the 100th year anniversary of when Dr Eric Von Willebrand first described the condition in a five year old girl. With this anniversary, we at the Canadian Hemophilia Society feel it's the perfect time to focus on increasing awareness, improving diagnosis, and addressing the fact that VWD remains under diagnosed and/or misdiagnosed. With that in mind, we're joined in this first episode by Dr. Dawn Goodyear, clinical associate professor and co-director of the southern Alberta rare blood and bleeding disorders program. Dr. Goodyear aims to give listeners a "101" style crash course on the ins and outs of Von Willebrand disease, as well as all of the currently available treatments.
This series is a creation of The Canadian Hemophilia Society - find out more at www.hemophilia.ca/von-willebrand-disease/
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
11 Feb 2026
Shared Decision-Making
Over the last several years, gene therapy for hemophilia B has become a reality. Some received it through clinical trials, and others received it after marketing authorizations and reimbursement approvals in their countries. Each of them had a difficult, life-changing decision to make. They needed to fully understand the potential benefits and risks, and the physicians responsible for their treatment needed to be assured that they were providing fully informed consent to the therapy. This process is called shared decision-making. In this episode of our second podcast series, GENE THERAPY FOR HEMOPHILIA – FROM DREAM TO REALITY, four people, two physicians and two people with hemophilia, were invited to share their insight on this topic.
Host: Sarah Ford, CEO, Canadian Hemophilia Society
Guest Speakers: Dr Pratima Chowdary, U.K.; Dr Davide Matino, Canada; Brian O'Mahony, Ireland; David Page, Canada
This series is a creation of The Canadian Hemophilia Society - to find out more go to www.hemophilia.ca/gene-therapy
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
11 Feb 2026
Four People Describe Their Experiences with Hemophilia B Gene Therapy
Over the last several years, gene therapy for hemophilia B has become a reality. Some received it through clinical trials. Others received it after marketing authorizations and reimbursement approvals in their countries. In this episode of our second podcast series, GENE THERAPY FOR HEMOPHILIA – FROM DREAM TO REALITY, four of these people were asked “Are you happy you made the decision to receive gene therapy? Why or why not?”
Host: David Page, Canadian Hemophilia Society
Guest Speakers: Daan Breederveld, Netherlands; Stephen Brown, Canada, John Curley, U.K.; Brian O'Mahony, Ireland
This series is a creation of The Canadian Hemophilia Society - to find out more go to www.hemophilia.ca/gene-therapy
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
28 Jan 2026
If Gene Therapy for Hemophilia B Were Available Tomorrow, Would You Want to Receive It?
For the last 40 years, we have witnessed tremendous advances in care and treatment for people with hemophilia. Gene therapy has been a dream for most of those 40 years, and the last two to three years, two gene therapies for hemophilia B have been approved by regulatory bodies. But are they for everybody? In this episode of our second podcast series, GENE THERAPY FOR HEMOPHILIA – FROM DREAM TO REALITY, we will ask four people with severe hemophilia B to answer this question, “If gene therapy for hemophilia B were available tomorrow, where you live, would you want to receive it?”
Host: Brian O’Mahony, Chief Executive, Irish Haemophilia Society
Guest Speakers: James Foley, Ireland; Brian O'Laughlin, Ireland; David Page, Canada; Joseph Walsh, Ireland
This series is a creation of The Canadian Hemophilia Society - to find out more go to www.hemophilia.ca/gene-therapy
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
28 Jan 2026
Overview of Gene Therapy Approaches
In this first episode of our second podcast series, GENE THERAPY FOR HEMOPHILIA – FROM DREAM TO REALITY, Dr. David Lillicrap describes what gene therapy is in 2026 and hopefully how it works. Dr. Lillicrap is a Professor in the Department of Pathology and Molecular Medicine at Queen’s University in Kingston, Ontario, and chair in Canadian Molecular Hemostasis Research.
Host: Brian O’Mahony, Chief Executive, Irish Haemophilia Society
Guest Speakers: James Foley, Ireland; Brian O'Laughlin, Ireland; David Page, Canada; Joseph Walsh, Ireland
This series is a creation of The Canadian Hemophilia Society - to find out more go to www.hemophilia.ca/gene-therapy
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
19 Feb 2025
WEBINAR 2: [FR] Un Pas en Arrière, Deux Pas en Avant
Le webinaire de la Société canadienne de l'hémophilie a abordé la thérapie génique pour les hémophiles. Dr. Jean St. Louis a expliqué les différences entre les injections de facteurs et la thérapie génique, en utilisant des vecteurs AAV pour introduire des gènes dans les cellules du foie. Il a détaillé les thérapies géniques approuvées par Santé Canada : MGX et Bec Vibes, soulignant leurs différences de dose et de taux d'échec. Les données à long terme montrent une réduction significative des saignements et une stabilité des niveaux de facteurs. Dr. David Page a discuté des défis de remboursement et de l'accès au traitement au Québec.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
17 Dec 2024
WEBINAR 2: [EN] Hemophilia Gene Therapy: One Step Back, Two Steps Forward
Dr. Roy Khalifé and David Page discuss the latest advancements and challenges in hemophilia gene therapy, highlighting the potential for improved treatment options and the need for equitable access across Canada.
5 Jun 2024
DEBATE: If gene therapy for hemophilia B were available in Canada tomorrow, would you want to receive it?
In this podcast, Elizabeth Vansant, Mark Pervan, Murray Milne and Mathieu Jackson, all individuals with severe hemophilia B, are asked to debate the question: “If gene therapy for hemophilia B were available in Canada tomorrow, would you want to receive it?”
See Privacy Policy at https://art19.com/privacy (https://art19.com/privacy) and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info (https://art19.com/privacy#do-not-sell-my-info).
28 Mar 2024
DEBATE: If gene therapy for hemophilia A were available in Canada tomorrow, Would you want to receive it?
In this podcast, Cleaven Pagani, Rick Waines, Paul Wilton and Emil Wijnker, all with severe hemophilia A and also members of the Canadian Hemophilia Society Blood Safety and Supply Committee, are asked to debate the question: “If gene therapy for hemophilia A were available in Canada tomorrow, would you want to receive it?”
See Privacy Policy at https://art19.com/privacy (https://art19.com/privacy) and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info (https://art19.com/privacy#do-not-sell-my-info).
18 Dec 2023
What Other Approaches To Hemophilia Gene Therapies Are Down The Road?
The first generation of gene therapy for hemophilia, called gene insertion or gene addition, is now a reality, but it is not for everyone. Dr. Glenn Pierce explores other approaches to gene therapy in the research pipeline that in the future may be more efficacious for a longer time for more people. Glenn is a long-time researcher in coagulation products for hemophilia and is currently the Medical Vice President of the World Federation of Hemophilia.
Canadian Hemophilia Society (https://www.hemophilia.ca/)
See Privacy Policy at https://art19.com/privacy (https://art19.com/privacy) and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info (https://art19.com/privacy#do-not-sell-my-info).
14 Dec 2023
How Might Gene Therapy Be Delivered In Canada?
In this podcast, Dr. Jerry Teitel explores how gene therapy for hemophilia A and hemophilia B might be delivered to patients across Canada in an equitable way, even though the administration will occur in only some sites. He describes the follow-up that is required in the critical months following administration to get the best results possible. Dr. Teitel is a Professor of Medicine at the University of Toronto, and Medical Director of the Hemophilia Treatment Program at St. Michael’s Hospital in Toronto, Ontario.
Canadian Hemophilia Society (https://www.hemophilia.ca/)
See Privacy Policy at https://art19.com/privacy (https://art19.com/privacy) and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info (https://art19.com/privacy#do-not-sell-my-info).
12 Dec 2023
How Might Gene Therapy Be Funded In Canada?
Gene therapy—a high-cost, one-time, potentially life-changing treatment—presents unique challenges for governments that make decisions on funding innovative treatments. Dr. Durhane Wong-Rieger presents creative ideas on new ways to think about how gene therapy for hemophilia A and B could be funded in Canada. Durhane is a health coach, frequent lecturer and author. She is the President and CEO of the Canadian Organization for Rare Diseases and chair of Rare Diseases International.
Canadian Hemophilia Society (https://www.hemophilia.ca/)
See Privacy Policy at https://art19.com/privacy (https://art19.com/privacy) and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info (https://art19.com/privacy#do-not-sell-my-info).
7 Dec 2023
What Is The Shared Decision-Making Process In Hemophilia Gene Therapy?
In this podcast, Dr. Jerry Teitel describes the process of shared decision-making prior to gene therapy in hemophilia A and hemophilia B, and how the nature of gene therapy itself makes shared decision-making so important. Dr. Teitel is a Professor of Medicine at the University of Toronto, and Medical Director of the Hemophilia Treatment Program at St. Michael’s Hospital in Toronto, Ontario.
Canadian Hemophilia Society (https://www.hemophilia.ca/)
See Privacy Policy at https://art19.com/privacy (https://art19.com/privacy) and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info (https://art19.com/privacy#do-not-sell-my-info).
5 Dec 2023
What Don’t We Know About Gene Therapy For Hemophilia?
In this podcast, Dr. Glenn Pierce explores what we know we don’t know and what we don’t even know we don’t know about the brand-new treatment which is gene therapy for hemophilia A and B. Glenn is a long-time researcher in coagulation products for hemophilia and is currently the Medical Vice President of the World Federation of Hemophilia.
Canadian Hemophilia Society (https://www.hemophilia.ca/)
See Privacy Policy at https://art19.com/privacy (https://art19.com/privacy) and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info (https://art19.com/privacy#do-not-sell-my-info).
1 Dec 2023
What Is It Like To Receive Gene Therapy?
In this podcast, Brian O’Mahony explores the patient experience of gene therapy for hemophilia, from the shared decision-making process prior to gene therapy, to the administration itself, to the intense follow-up in the first months and finally, the long-term follow-up. Brian is Chief Executive Officer of the Irish Haemophilia Society and a former president of the World Federation of Hemophilia and the European Haemophilia Consortium.
Canadian Hemophilia Society (https://www.hemophilia.ca/)
See Privacy Policy at https://art19.com/privacy (https://art19.com/privacy) and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info (https://art19.com/privacy#do-not-sell-my-info).
30 Nov 2023
What Are The Clinical Trial Results In Hemophilia Gene Therapy?
In this podcast, Dr. David Lillicrap presents the results of clinical trials in hemophilia A and hemophilia B gene therapy. He describes how high factor VIII and IX levels can rise, how predictable this response is from person to person, and how long the therapy may be effective. Dr. Lillicrap is a Professor in the Department of Pathology and Molecular Medicine at Queen’s University in Kingston, Ontario, and is world renowned for his research in hemophilia gene therapy.
Canadian Hemophilia Society (https://www.hemophilia.ca/)
See Privacy Policy at https://art19.com/privacy (https://art19.com/privacy) and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info (https://art19.com/privacy#do-not-sell-my-info).
17 Nov 2023
Who Is Eligible For Hemophilia Gene Therapy?
In this podcast, Brian O’Mahony explores why gene therapy for hemophilia A and Hemophilia B is not for all patients. He describes what makes a person eligible, and in some cases ineligible, to receive the treatment. Brian is Chief Executive Officer of the Irish Haemophilia Society and a former president of the World Federation of Hemophilia and the European Haemophilia Consortium.
Canadian Hemophilia Society (https://www.hemophilia.ca/)
See Privacy Policy at https://art19.com/privacy (https://art19.com/privacy) and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info (https://art19.com/privacy#do-not-sell-my-info).
16 Nov 2023
What Is Gene Therapy For Hemophilia?
In this podcast, Dr. David Lillicrap describes in easy-to-understand language what gene therapy for hemophilia A and hemophilia B is, how it is administered and how it works. Dr. Lillicrap is a Professor in the Department of Pathology and Molecular Medicine at Queen’s University in Kingston, Ontario, and is world renowned for his research in hemophilia gene therapy.
Canadian Hemophilia Society (https://www.hemophilia.ca/)
See Privacy Policy at https://art19.com/privacy (https://art19.com/privacy) and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info (https://art19.com/privacy#do-not-sell-my-info).
15 Nov 2023
Introducing: Gene Therapy for Hemophilia: Dream or Reality?
This is a series of podcasts featuring well-known patient and physician experts will provide important answers, for example: What are the clinical trial results in hemophilia GT? What is the shared decision-making process in hemophilia GT? What is it like to receive it? What other approaches to hemophilia GTs are down the road?
David Page is your host and explores the possibilities with medical experts.
See Privacy Policy at https://art19.com/privacy (https://art19.com/privacy) and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info (https://art19.com/privacy#do-not-sell-my-info).
Podcast Authority Score: 17 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
34
Social presence
0
YouTube
0
Engagement
0
Contact Gene Therapy for Hemophilia: Dream or Reality?
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Gene Therapy for Hemophilia: Dream or Reality??
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
